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Objective To investigate the effect of simple head cooling combined with 
ganglioside therapy on neonatal hypoxic-ischemic encephalopathy (HIE) 
and its clinical efficacy. Methods A total of 100 children with HIE admitted 
in the neonatal ward of our hospital from August 2018 to October 2020 
were selected as the research objects, and were divided into control group 
and observation group according to the random number table method, with 
50 cases in each group. The control group was treated with gangliosides, 
and the observation group was treated with simple head cooling combined 
with gangliosides. Observe and compare the clinical performance 
improvement time, the level of relevant hematological examination indexes 
before and after treatment, and the neonatal behavioral neurological 
assessment (NBNA), clinical efficacy, and adverse reactions. Results The 
improvement time of convulsions, disturbance of consciousness, pupil 
changes, hypotonia, and gastrointestinal dysfunction in the observation 
group was significantly lower than that in the control group (all P<0.001). 
After treatment, the NSE, IL-6, CK, CK-MB of the two groups of children 
were significantly lower than before treatment, and the serum calcium 
and NBNA scores were significantly higher than before treatment, and the 
decrease or increase in the observation group was significantly higher than 
that of the control Group (all P<0.001). The total effective rate of treatment 
of children in the observation group (82.00%) was higher than that of the 
control group (62.00%) (P<0.05). There were no obvious adverse reactions 
in both groups. Conclusion The simple head cooling combined with 
gangliosides in the treatment of HIE can improve the clinical symptoms, 
blood test index levels, and NBNA scores. The clinical effect is clear and 
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1. Introduction
Neonatal hypoxic-ischemic encephalopathy (HIE) is one of the common results in neonatal brain damage caused by hypoxic-ischemia because 
of perinatal asphyxia. HIE seriously threatens the health 
and life of newborns , About 25%-30% of surviving sick 
newborns are at risk of neurological sequelae, including 
epilepsy, intellectual disability, cerebral palsy, etc [1]. The 
pathophysiological changes of HIE are not yet fully un-
derstood, leading to lack of breakthrough treatment meth-
ods. At present, comprehensive support and symptomatic 
treatment are still the main components of standard treat-
ment programs. Mild hypothermia therapy has a clear 
neuroprotective effect, which can reduce the mortality 
of HIE and the rate of long-term severe disability. It has 
been regarded as the standard treatment for moderate and 
severe HIE[2]. In consideration of the safety, complexity 
and cost of standard hypothermia therapy, we use simple 
head cooling to achieve the purpose of treatment in clinic. 
At the same time, drug therapy is also an important part of 
HIE treatment. Gangliosides can maintain membrane in-
tegrity and regulate brain development. They can prevent 
cell apoptosis and reduce brain damage. They are widely 
used as auxiliary drugs for HIE in my country. Under 
treatment [3]. There are not many clinical reports about 
simple head cooling combined with ganglioside in the 
treatment of HIE. This study aims to explore the clinical 
effect of this treatment regimen in the treatment of HIE 
and its influence on related observation indicators.
2. Information and Methods
2.1 General Information
100 children with HIE admitted in the neonatal ward of 
our hospital from August 2018 to October 2020 are select-
ed as the research objects, and the random number table 
method is used to divide them into the control group and 
the observation group with 50 cases each. The comparison 
of general data (gender, delivery method, clinical scale, 
gestational age, birth weight, Apgar score at 5 minutes 
after birth) between the two groups showed no significant 
difference (P>0.05) and was comparable. Inclusion cri-
teria: (1) Meet the diagnostic criteria for neonatal hypox-
ic-ischemic encephalopathy established by the Neonatal 
Group of the Pediatric Branch of the Chinese Medical 
Association[4], and determine the clinical scale based on 
this diagnostic criteria; (2) both Full-term infant and birth 
weight ≥2500g; (3) Receive treatment within 6 hours 
of onset of illness; (4) With the informed consent of the 
child’s family member and sign a letter of commitment. 
Exclusion criteria: (1) Patients with pregnancy compli-
cations during pregnancy; (2) Patients with spontaneous 
bleeding tendency; (3) Patients with complicated and re-
fractory congenital malformations, acute brain-related dis-
eases, congenital infections and other related diseases (4) 
Those who are contraindicated with this treatment drug; (5) 
Those who give up treatment. This clinical study followed 
the Declaration of Helsinki and passed the review of the 
Medical Ethics Committee of our hospital.
2.2 Method
After admission, the two groups were actively treated 
with routine treatments, namely three maintenance treat-
ments (maintain good ventilation and ventilation function; 
maintain sufficient blood perfusion of the whole body 
and various organs; maintain high normal blood glucose), 
three symptomatic treatments (control convulsions, Con-
vulsions; reduce intracranial pressure; eliminate brainstem 
symptoms). The control group was treated with monosia-
lotetrahexose ganglioside sodium (produced by Harbin 
Medical University Pharmaceutical Co., Ltd., approval 
number: Zhunzi H20060422, specification: 20mg) on 
the basis of conventional treatment. The injection was 
dissolved and diluted with 20ml 5% glucose, injected 
intravenously with a dosage of 20 mg each time, once a 
day, for continuous treatment for 14 days; the observation 
group was given a simple head cooling treatment based 
on the treatment of the control group, starting within 6 
hours of onset, using ice force Apply the cooling patch to 
the skin of the child’s forehead. At the same time, use a 
gel ice pack to evenly wrap around the child’s head. Re-
place every hour during the operation to ensure that the 
temperature of the ice pack and cooling patch is at 7-10°C, 
and monitor the child’s anus. Keep the rectal temperature 
at 33-34℃ , and monitor the vital signs of the child. Con-
tinuous treatment for 72 hours, and slowly and naturally 
rewarming after the treatment.
2.3 Observation Indicators
(1) Collect and compare the general data of the two 
groups of children; (2) Record and compare the improve-
ment time of related clinical manifestations (convulsions, 
consciousness disturbance, pupil changes, hypotonia, gas-
trointestinal dysfunction) of the two groups of children; 
(3) Compare the blood test index levels of the two groups 
of children before and after treatment. Before and after 
treatment, 5ml of radial venous blood was drawn from the 
two groups of children. All blood samples were placed in 
blood collection tubes. After centrifugation at 3500r/min, 
the serum was separated and stored in a freezer at -15°C 
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for inspection. Enzyme-linked immunosorbent assay 
(ELISA) detects serum neuron-specific enolase (NSE) and 
serum interleukin-6 (IL-6) levels. The kits are all made by 
Kamisu ( Provided by Shanghai) Biotechnology Co., Ltd. 
The operation method is strictly in accordance with the 
instruction manual. Use a biochemical analyzer to detect 
serum calcium, creatine kinase (CK) and MB isoenzyme 
of creatine kinase (CK-MB) levels; (4) Compare the nerve 
function score of the two groups of children before and 
after treatment. Before and after treatment, a systematical-
ly trained specialist used the 20-item neonatal behavioral 
neurological assessment (NBNA) developed by Professor 
Bao Xiulan [5] to conduct behavioral neurological assess-
ment and scores on the two groups of children. , Including 
5 parts of behavioral ability, passive muscle tone, active 
muscle tone, original reflex and general evaluation. There 
are 20 assessment items, using a 0-2 point scoring system, 
with a full score of 40 points, and a total score of ≥35 
points as neurological Normal function, a total score of 
less than 35 points is regarded as abnormal neurological 
function. The lower the score, the more serious the brain 
injury and the worse the behavioral neurological evalua-
tion. (5) Compare the clinical efficacy of the two groups 
of children after treatment. An attending and above spe-
cialist physician will evaluate the treatment effect of the 
children. After treatment, related clinical symptoms such 
as consciousness disturbance, respiratory failure, abnor-
mal muscle tone, seizures, pupil changes, etc. returned 
to normal, the amplitude integrated EEG was normal, 
and the blood test indicators returned to normal, it is re-
markable. After treatment, the above-mentioned clinical 
symptoms and related examinations have been significant-
ly improved and have basically returned to normal after 
treatment, it is effective. After treatment, the above-men-
tioned clinical symptoms and related examinations are not 
significantly improved, or even worse than before, it is 
invalid. Total effective rate = (remarkable number + effec-
tive number)/total × 100%. (6) Record the adverse reac-
tions during the treatment of the two groups of children.
2.4 Statistical Processing 
Use spss26.0 statistical software for statistical analysis 
and processing of all data. The measurement data con-
forming to the normal distribution are expressed by the 
mean ± standard deviation (x±s), the comparison within 
the group adopts the paired design t test, and the compar-
ison between the groups adopts the t test of the mean of 
two independent samples; the count data is expressed by 
[n(%)] Indicates that the x2 test is used. P<0.05 means the 
difference is statistically significant.
3. Results
3.1 Comparison of the General Data of the Two 
Groups of Children
There was no statistical difference in the general data 
of the two groups of children (gender, delivery method, 
clinical grade, gestational age, birth weight, admission 
age, Apgar score at 5 minutes after birth) Significance 
(P>0.05). See Table 1.
3.2 Comparison of the Improvement Time of 
the Related Clinical Manifestations of the Two 
Groups of Children
The improvement time of the related clinical manifesta-
tions including convulsions, disturbance of consciousness, 
pupil changes, hypotonia, and gastrointestinal dysfunction 
in the observation group was lower than that of the control 
group. Academic significance (P＜ 0.001). See Table 2.
3.3 Comparison of Blood Test Index Levels before 
and after Treatment between the Two Groups of 
Children
Before treatment, there was no statistically significant 
difference between the two groups of children in the NSE, 
IL-6, serum calcium, CK, and CK-MB index levels (P> 
0.05), comparable. After treatment, the levels of NSE, IL-
6, CK, and CK-MB of the two groups of children were 














Apgar score at 5 
minutes after birth 
(x±s, points)
control group 50 27/23 24/26 26/24 39.56±1.25 3.61±1.22 3.28±0.25 3.86±0.83
observation group 50 28/22 27/23 25/25 39.76±1.04 3.52±1.37 3.36±0.18 3.84±1.13
x2/t - 0.040* 0.360* 0.040* -0.870 0.353 -1.656 0.101
P - 0.841 0.548 0.841 0.386 0.725 0.101 0.920
Note: * is the value of x2.
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lower than before treatment, and the difference was statis-
tically significant (P<0.001); after treatment, the levels of 
serum calcium index of the two groups of children were 
both Higher than before treatment, the differences were 
statistically significant (P<0.001). After treatment, the 
levels of NSE, IL-6, CK, and CK-MB in the observation 
group were significantly lower than those in the control 
group, and the differences were statistically significant 
(P<0.001); after treatment, the observation group Serum 
calcium index levels were significantly higher than those 
in the control group, and the difference was statistically 
significant (P<0.001). See Table 3.
3.4 Comparison of NBNA Scores between the Two 
Groups of Children before and after Treatment
Before treatment, there was no significant difference 
in NBNA scores between the two groups of children 
(P>0.05), and they were comparable. After treatment, the 
NBNA scores of the two groups of children were higher 
than those before treatment, and the difference was statis-
tically significant (P<0.001). After treatment, the NBNA 
scores of children in the observation group were higher 
than those in the control group, and the difference was 
statistically significant (P<0.001). See Table 4.
3.5 Comparison of Clinical Efficacy between the 
Two Groups of Children after Treatment
The total effective rate of treatment in the observation 
group (82.00%) was higher than that of the control group 
(62.00%), and the difference was statistically significant 
(P<0.05). See Table 5.
Table 2. Comparison of improvement time of related clinical manifestations between the two groups of children (x±s, d)
Groups Cases Convulsions Disturbance of consciousness Pupil changes Hypotonia Gastrointestinal dysfunction
Control group 50 6.54±2.12 5.46±1.72 3.46±1.66 8.82±1.88 4.66±1.36
Observation group 50 3.70±1.15 3.60±1.44 2.32±0.98 6.34±1.77 3.22±1.18
t - 8.328 5.865 4.191 6.792 5.638
P - 0.000 0.000 0.000 0.000 0.000
Table 3. Comparison of blood test index levels before and after treatment in the two groups of children (x±s)
Groups Cases


















group 50 49.17±6.22 29.75±4.39* 81.36±8.48 46.38±9.05* 1.68±0.22 1.83±0.21* 309.51±36.19198.33±19.64* 52.83±8.22 33.09±6.49*
Observation 
group 50 48.78±5.83 19.58±3.75* 80.77±7.94 29.53±8.33* 1.70±0.23 2.04±0.19* 311.59±36.25 165.55±17.79* 53.27±8.49 25.23±4.07*
t - 0.323 12.453 0.353 9.687 -0.227 -5.113 -0.287 8.744 -0.269 7.266
P - 0.747 0.000 0.725 0.000 0.821 0.000 0.775 0.000 0.789 0.000
Note: Compared with before treatment, * P＜ 0.001.
Table 4. Comparison of NBNA scores of the two groups of children before and after treatment (x±s, points)
Groups Cases before treatment after treatment t P
Control group 50 26.31±2.84 33.22±2.97 -79.866 0.000
Observation group 50 25.91±2.88 37.39±3.60 -80.067 0.000
t - 0.717 -6.333
P - 0.475 0.000
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3.6 Adverse Reactions during the Treatment of 
the Two Groups of Children 
No obvious adverse reactions occurred in the two groups 
of children.
4. Discussion
Neonatal encephalopathy after postpartum related events 
is one of the main causes of neonatal diseases in the 
world. Under the condition that there is a causal relation-
ship between neonatal encephalopathy and hypoxic-isch-
emic brain damage, it is called neonatal hypoxic-ischemic 
encephalopathy (HIE). Refers to the complex pathophysi-
ological and cellular molecular changes caused by severe 
hypoxic-ischemic brain damage in the neonatal period. 
HIE is not a single event, but a continuous process [6]. 
Existing studies have shown [7] that the pathophysiologi-
cal reaction process of HIE is mediated by an excitatory 
oxidation cascade, and the first energy failure that occurs 
is characterized by the reduction of ATP production and 
the increase in lactic acid or acidosis. the second energy 
failure seems to be related to oxidative stress, inflam-
matory response, excitotoxicity and eventual cell death. 
The continuous cascade of reactions will further prevent 
neuronal regeneration or aggravate brain damage, thereby 
forming a tertiary brain injury . The above cascade can 
also be summarized into five main events, namely oxida-
tive stress, mitochondrial dysfunction, intracellular calci-
um ion overload, excitotoxicity and inflammation. After 
modern basic medicine gradually understood the progress 
of the brain injury mediated by this cascade reaction at 
the cellular molecular level and better clarified its basic 
mechanism, it began to actively study different potential 
neuroprotective therapies and adjuvant therapies, through 
intervention in the cascade reaction or an important step 
to protect the brain tissue. These promising neuroprotec-
tive agents have been tested in animal models and prelim-
inary clinical studies of HIE, targeting different stages of 
injury: early excitotoxicity, oxidative stress and apoptosis, 
late inflammation, and neuronal and Regeneration of 
oligodendrocytes, a variety of drug treatments designed, 
such as mitochondrial membrane stabilizers, neurotrophic 
factors, etc.[8]. Experimental studies have shown [9] that hy-
pothermia treatment can inhibit key steps in the cascade, 
including reducing the destructive effects of secondary 
energy failure on the brain, slowing down oxidative stress, 
antagonizing the release of excitatory neurotransmitters, 
and reducing cells Apoptosis and so on. With the emer-
gence of mild hypothermia treatment and its widespread 
clinical application, the prognosis of moderate HIE has 
been significantly improved, and early hypothermia treat-
ment within 3 hours after birth has gradually attracted the 
attention of clinicians [10].
Mild hypothermia treatment is part of the standard 
treatment plan in developed areas, but it is still an ex-
pensive and unacceptable treatment in a resource-limited 
environment and requires a professional team to imple-
ment it. Taking into account the limitations of profession-
al hypothermia treatment, low-cost, easy-to-access and 
use cooling methods and treatment plans are required in 
clinical work to ensure its applicability [11]. Studies have 
shown that [12] gel ice packs can be safely and effectively 
successfully induced hypothermia. Therefore, we adopted 
the above-mentioned low-cost and reusable simple head 
cooling method, which is more acceptable to family mem-
bers of patients. During treatment no obvious adverse 
reactions occurred. Sheng et al. [13] evaluated 10 Chinese 
RCT trials with 987 newborns and concluded that mono-
sialoganglioside adjuvant treatment of HIE can provide 
additional benefits in improving short-term clinical effects 
and reducing long-term neurodevelopmental disorders. 
Exogenous monosialogangliosides can stably bind to 
nerve cell membranes, leading to changes in membrane 
function. Its mechanism of action is to promote nerve cell 
survival, axon growth and synaptic growth, which makes 
monosialogangliosides in my country is widely used in 
the clinical adjuvant treatment of HIE and has shown reli-
able results. At present, the application effect of these two 
common clinical treatments for HIE is still unclear. We 
conducted research on this basis.
The serum level of NSE is very low at physiological 
level, only exists in nerve cells, and is released outside the 
Table 5. Comparison of the clinical efficacy of the two groups of children
Groups Cases Remarkable (n) Effective (n) Invalid (n) Total effective [n( %)]
Control group 50 12 20 19 31(62.00)
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cell when neuron damage occurs, and enters the peripheral 
blood through the blood-brain barrier. NSE can be used as 
an early sensitive indicator of nerve cell damage. The se-
verity of HIE is positively correlated and decreases as the 
disease improves[14]. IL-6 is a multifunctional immune me-
diator that regulates cellular immunity and inflammatory 
response. A few minutes after hypoxia and ischemia, the 
levels of IL-6 and other inflammatory cytokines increase 
rapidly, by inducing neuronal apoptosis and increasing 
toxic factors. Nitric oxide levels promote hypoxic-isch-
emic brain damage[15]. Hypocalcemia is a common disease 
of HIE. In the reperfusion stage after hypoxic-ischemic 
injury, rapid calcium influx into cells is ATP-dependent 
Na+-K+ pump failure and cell necrosis secondary to mem-
brane depolarization Or the main cause of apoptosis, the 
influx of calcium ions into the cells of multiple damaged 
organs will reduce the serum calcium concentration[16]. 
When a newborn is asphyxiated, hypoxia and hemody-
namic pathological changes can cause hypoxic-ischemic 
myocardial damage and abnormal levels of myocardial 
enzyme spectrum[17]. In terms of the above hematological 
examination indicators, this study shows that after the 
single use of ganglioside treatment, the levels of related 
indicators are improved compared to before treatment, 
which indicates that gangliosides can promote nerve cell 
regeneration and reduce nerve cell destruction. Nutritional 
effect may inhibit the inflammatory response after injury, 
calcium influx into cells and hypoxic-ischemic myocardi-
al damage; and after simple head cooling combined with 
ganglioside treatment, the improvement effect of related 
index levels is better than that of using ganglioside alone 
Better, it indirectly suggests that the combination therapy 
can repair nerve damage to a greater extent, inhibit cell 
apoptosis and oxidative stress, and better inhibit the pro-
duction of active mediators to participate in pathophysio-
logical reactions, thereby reducing IL-6 secretion and re-
ducing calcium ion internal Intracellular overload caused 
by flow and promote the recovery of myocardial enzyme 
spectrum level. In terms of NBNA score, in this study, the 
NBNA score after combined treatment was higher than 
that of ganglioside alone, which shows that combined 
treatment may have a more positive effect on nervous 
system rehabilitation and long-term nervous system devel-
opment. This is also true in terms of clinical symptom im-
provement time and therapeutic efficacy. The total clinical 
effective rate and related clinical symptom improvement 
time after combined treatment are better than single treat-
ment. This reflects that simple head cooling can exert the 
effect of hypothermia treatment. This combined treatment 
It may have a synergistic effect to effectively prevent 
the further progression of the disease, thereby improving 
the overall efficacy. The disadvantage is that the study is 
retrospective, conducted in one center, and the data is lim-
ited. Future studies may need to increase the sample size 
and conduct multi-center cooperation.
5. Conclusion
The current research on the treatment of HIE has shifted 
from single hypothermia treatment to seeking to improve 
the prognosis of children by adding adjuvant drug therapy 
to the treatment of mild hypothermia[18]. This study in-
troduces a Basically similar treatment options for limited 
conditions. In summary, simple head cooling combined 
with gangliosides for HIE can significantly improve clini-
cal symptoms, blood test index levels, and NBNA scores. 
The clinical efficacy is clear and superior to single gangli-
oside therapy.
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